Raymond James Financial
CCCC icon

Raymond James Financial’s C4 Therapeutics CCCC Stock Holding History

Raymond James Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-135
Closed -$193 – 5256
2025
Q2 		$193 Buy
+135
New +$196 ﹤0.01% 6787

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's CCCC Position: Q3 2025 in Review

Raymond James Financial sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 135 shares — an estimated $193 sold.

Raymond James Financial first reported a position in CCCC in Q2 2025 and held it in 1 quarter. The position peaked at $193 in Q2 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Raymond James Financial reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 135 C4 Therapeutics shares in Q3 2025, an estimated $193.
  • Raymond James Financial first reported a position in C4 Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's C4 Therapeutics position peaked at $193 in Q2 2025.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.